Streetbeat News

Stock Prices

SPY

The U.S. Core PCE Prices for Q2 came in at 3.70%, matching the forecast and lower than the previous 4.90%.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 12:32 pm

SPY

The Q2 PCE Prices came in as expected at 2.5%.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 12:31 pm

SPY

The USA GDP for Q2 has been reported at 2.1%, matching the estimated figure and showing a slight increase from the prior 2.0%.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 12:30 pm

ASPU

FBIO

GOVX

RCAT

Insiders at four penny stocks, Aspen Group, Inc. (OTC:ASPU), Fortress Biotech, Inc. (NASDAQ:FBIO), Red Cat Holdings, Inc. (NASDAQ:RCAT), and GeoVax Labs, Inc. (NASDAQ:GOVX), have recently made notable purchases. Aspen Group recently closed a $12.4 million private placement. Fortress Biotech posted a narrower loss for Q2. Red Cat Holdings posted an in-line loss for Q1. GeoVax Labs and ProBioGen signed a landmark commercial license agreement for ProBioGen's AGE1.CR.pIX® suspension cell line.

Portfolio Pulse from Lisa Levin

September 28, 2023 | 12:29 pm

FOLD

Shares of Amicus Therapeutics have been halted due to pending news. The nature of the news is currently unknown.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 12:29 pm

DYNT

Dynatronics Corp has reiterated its previous net sales guidance for FY24 of $34M-$37M, which is in line with the estimated $35.5M.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 12:25 pm

BNOX

Bionomics Limited (NASDAQ:BNOX) announced positive results from its Phase 2b ATTUNE trial of BNC210 for post-traumatic stress disorder (PTSD). The trial met its primary endpoint and showed significant improvements in depressive symptoms and sleep. The company also held a Phase 3-enabling End-of-Phase 2 meeting with the FDA to advance BNC210 for the acute treatment of social anxiety disorder. BNOX shares are up 387.30% at $4.80 during the premarket session.

Portfolio Pulse from Vandana Singh

September 28, 2023 | 12:24 pm

DYNT

Dynatronics reported Q4 losses of $(0.63) per share, missing the analyst consensus estimate of $(0.28) by 125 percent, a 26 percent decrease over losses from the same period last year. However, the company's quarterly sales of $8.44 million beat the analyst consensus estimate of $7.86 million by 7.35 percent, despite a 24.60 percent decrease over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 12:22 pm

LLY

NVO

Prescriptions for diabetes and obesity drugs like Ozempic and Wegovy have surged 300% from early 2020 to the end of 2022, according to an analysis by Trilliant Health. Novo Nordisk's Ozempic accounted for over 65% of total prescriptions. Eli Lilly's Mounjaro and Novo Nordisk's Saxenda have also been prescribed. The surge can be attributed to their ability to induce significant weight loss. However, future prescription volumes depend on resolving supply shortages faced by Novo Nordisk and Eli Lilly in the U.S.

Portfolio Pulse from Vandana Singh

September 28, 2023 | 12:22 pm

BCLI

The FDA's Cellular, Tissue and Gene Therapies Advisory Committee has voted against the effectiveness of BrainStorm Cell Therapeutics Inc's (NASDAQ:BCLI) NurOwn application for the treatment of mild to moderate ALS. The FDA staff reviewers had previously raised concerns over the safety and efficacy of the therapy. Last year, BrainStorm Cell received a refusal to file a letter from the FDA regarding its marketing application seeking approval for NurOwn. BCLI shares are down 54.30% at $0.19 during the premarket session on the last check Thursday.

Portfolio Pulse from Vandana Singh

September 28, 2023 | 12:20 pm